Dr. Ross Camidge, M.D., Ph.D.
Following a PhD in Molecular Biology at the Medical Research Council’s Laboratory of Molecular Biology at Cambridge University, UK, Dr Camidge completed his medical training at Oxford University, UK. He then became the first person to double train in Medical Oncology and Clinical Pharmacology in the UK, before joining the University of Colorado, USA from October 2005.
The Colorado Multidisciplinary Thoracic Oncology Program is internationally recognized. Over 20% of it’s in-person patients travel from outside of Colorado, the highest of any program in the cancer center and separate from the even greater reach of the program’s ground-breaking national and international remote second opinion program. Included in the program are three thoracic surgeons, three thoracic radiation oncologists, three thoracic pathologists/molecular pathologists, three thoracic radiologists, three pulmonologists (running the pulmonary nodule clinic) and six thoracic medical oncologists (with the support of two medical oncology NPs, clinic nurses, a dietician, a social worker and an embedded PharmD). The program has direct faculty representation across UCHealth linked sites at Highlands Ranch, LoneTree and Cherry Creek and close relations with the UCHealth oncology practitioners treating thoracic cancers across the network.
The central Program accrues 40% of its lung cancer patients onto clinical trials, approximately double that of the next best NCI cancer center and ten times the national average.
Dr Camidge’s main areas of clinical and research interest are thoracic malignancies and developmental therapeutics. The discoveries he and the Colorado team have made have changed the standard of care for the treatment of lung cancer multiple times. He has authored over 250 academic publications, including in the Journal of Thoracic Oncology, Journal of Clinical Oncology, Lancet Oncology, and New England Journal of Medicine. He has presented his work at numerous national and international meetings.
In 2012 he received the Bonnie J. Addario International Lectureship Award as a ‘Luminary in the quest to eradicate lung cancer’. In 2013 he became the first physician to receive the Hank Baskett Sr. Spirit Award, for which he was credited as being ‘one of the leading minds in lung cancer today’. In 2014, he was nationally recognized by The Quality of Life Center at Claremont University in California as an ‘Exemplary mentor in the positive development of junior colleagues in the profession’. In 2016, the Lung Cancer Foundation presented him with the Breath Away From The Cure Award describing him as ‘Simply one of the best in treating lung cancer today’.
Every year from 2017, he has been internationally recognized as a highly cited researcher ranked in the top 1% of all of Clinical Medicine by Clarivate Analytics Web of Science. In 2019 and 2020 he was ranked at the ‘World Expert’ level by Expertscape and recognized to be in the top 0.0043% of scholars writing about Lung Neoplasms over the past 10 years. He is also the National Medical Director of the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC), Co-chair of the Elsevier ClinPath (formerly VIA) Oncology Lung Cancer Pathways Committee and a past-member of the National Comprehensive Cancer Network Lung Cancer Committee.